The prospective randomized trial evaluating the efficacy of the mitomycin C and cisplatin regimen (MP) versus standard first-line chemotherapy in patients with advanced BRCA1/2-associated ovarian cancer (NCT04747717). Вопр. онкол. [Internet]. 2022 Oct. 27 [cited 2026 Oct. 15];68(5):628-3. Available from: https://voprosyonkologii.ru/index.php/journal/article/view/1411